NCT02029209View on ClinicalTrials.gov

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Anlotinib

Anlotinib QD

DRUG

Placebo Capsule

Placebo capsule QD

Trial Locations (1)

300600

20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital ., Tianjin

Sponsors
All Listed Sponsors
collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY